For patients with breast cancer

Oncotype DX Breast Recurrence Score

If you’ve been recently diagnosed with early stage, estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer, the Oncotype DX Breast Recurrence Score test can help you and your doctor understand what treatment options are right for you—including whether you’re likely to benefit from chemotherapy.1,2^1,2

The Breast Recurrence Score test looks at several cancer-related genes in your tumor tissue. Because every woman’s tumor is unique, understanding the biology of your specific tumor will help you and your doctor make more confident decisions about your care.

Do I need chemotherapy?

The Oncotype DX Breast Recurrence Score test is a diagnostic test that measures the activity of a group of cancer genes in a woman’s breast cancer tissue. The test gives you information about:

The test takes place on cancer tissue removed at the time of surgery, so no additional surgery is required.

Am I eligible for the test?

Your healthcare professional will discuss this with you. The criteria for eligibility are that you:^2,3

• are newly diagnosed with early stage invasive breast cancer
• have cancer cells that are ER+
• have cancer cells that are HER2 negative
• are either lymph node negative or 1-3 lymph nodes positive.

Understanding your Recurrence Score result

The result of the Oncotype DX Breast Recurrence Score test is called the Recurrence Score result, which can be any number from 0 to 100. The lower the Recurrence Score result is, the less likely you are to benefit from chemotherapy; the higher the Recurrence Score result is, the more likely you are to benefit from chemotherapy.

It is important to understand that a lower Recurrence Score result does not mean there is no chance that the cancer will return. Similarly, a higher result does not mean that chemotherapy will definitely prevent the cancer from returning.

How long does it take?

A small amount of breast cancer tissue that was removed during your original surgery is selected by the pathologist and sent to a central laboratory for testing. Testing in a central laboratory ensures the quality assurance of the test result. The activity of genes in the cancer cells is analyzed. After the gene activity analysis is complete, a written report is prepared and sent electronically to your healthcare professional. The whole process takes about 10 days.

Is the test reliable?

To date, the Breast Recurrence Score test has been ordered in over 900,000 patients.³ Many women who received high Recurrence Score results were able to choose chemotherapy as a potentially life-saving treatment. The majority of women with low Recurrence Score results were able to effectively pursue hormonal therapy alone and avoid the unnecessary side effects of chemotherapy.^4-11

Clinical Guidelines

Oncotype DX Breast Recurrence Score test is incorporated in Modrá Kniha¹² of Czech Oncology Society and is included in all major internationally recognized clinical guidelines for breast cancer such as American Society of Clinical Oncology (ASCO®), National Comprehensive Cancer Network (NCCN®), St. Gallen Consensus panel, National Institute for Health Care Excellence (NICE), European Society for Medical Oncology (ESMO) and German Association of Gynecological Oncology (AGO).^13-18*

Contact us

For more information about the test contact us.

References

1. Paik et al. N Engl J Med. 2006.
2. Albain et al. Lancet Oncol. 2010.
3. Data on file. Genomic Health Inc.
4. Sparano et al. N Engl J Med. 2015.
5. Gluz et al. J Clin Oncol. 2016.
6. Stemmer et al. SABCS 2015.
7. Petkov et al. npj Breast Cancer. 2016.
8. Shak et al. ASCO QCS 2016.
9. Stemmer et al. ESMO 2016.
10. Roberts et al. Breast Cancer Res Treat. 2017
11. Shak et al. ESMO 2016.
12. Modrá kniha, Linkos.cz
13. Harris et al. J Clin Oncol. 2016.
14. NCCN Clinical Practice Guidelines in Oncology. V.2.2017.
15. NICE Diagnostics Guidance 10. 2013.
16. Senkus et al. Ann Oncol. 2015.
17. Coates et al. Ann Oncol. 2015.
18. www.ago-online.de Guidelines Breast Cancer.

*American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and NCCN do not endorse any product or therapy